Campbell, B.A.; Scarisbrick, J.J.; Kim, Y.H.; Wilcox, R.A.; McCormack, C.; Prince, H.M.
Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers 2020, 12, 2311.
https://doi.org/10.3390/cancers12082311
AMA Style
Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM.
Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers. 2020; 12(8):2311.
https://doi.org/10.3390/cancers12082311
Chicago/Turabian Style
Campbell, Belinda A., Julia J. Scarisbrick, Youn H. Kim, Ryan A. Wilcox, Christopher McCormack, and H. Miles Prince.
2020. "Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma" Cancers 12, no. 8: 2311.
https://doi.org/10.3390/cancers12082311
APA Style
Campbell, B. A., Scarisbrick, J. J., Kim, Y. H., Wilcox, R. A., McCormack, C., & Prince, H. M.
(2020). Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers, 12(8), 2311.
https://doi.org/10.3390/cancers12082311